

- Rosenberg B, VanCamp L, Troso J, et al. Platinum compounds: a new class of potent antitumor agents. *Nature* 1969;222:385–386.
- Rosenberg B. Fundamental studies with cisplatin. *Cancer* 1985;55:2303–2316.
- Cvitkovic E, Spaulding J, Bethune V, et al. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. *Cancer* 1977;39:1357–1361.
- Hayes D, Cvitkovic E, Golbey R, et al. High dose cis-platinum diamine dichloride: amelioration of renal toxicity by mannitol diuresis. *Cancer* 1977;39:1372–1381.
- Roberts J, Thomson A. The mechanism of action of antitumor platinum compounds. *Nucleic Acids Res* 1979;22:71–133.
- Martin R. Platinum complexes: hydrolysis and binding to N(7) and N(1) of purines. In: Lippert B, ed. *Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug*. Zurich: Verlag Helvetica Chimica Acta; 1999:183.
- Harrap K. Preclinical studies identifying carboplatin as a viable cisplatin alternative. *Cancer Treat Rev* 1985;12:A21–A33.
- Harrap K. Initiatives with platinum- and quinazoline-based antitumor molecules—Fourteenth Bruce F. Cain Memorial Award Lecture. *Cancer Res* 1995;55:2761–2768.
- Calvert A, Newell D, Gumbrell L, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 1989;7:1748–1756.
- Egorin M, Echo DV, Olman E, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatin(II) analogue diamminocyclobutanedicarboxylatoplatin. *Cancer Res* 1985;45:6502–6506.
- Connors T, Jones M, Ross W, et al. New platinum complexes with antitumor activity. *Chem Biol Interact* 1972;5:415–424.
- Burchenal J, Kalaker K, Dew K, et al. Rationale for development of platinum analogs. *Cancer Treat Rep* 1979;63:1493–1498.
- Kidani Y, Inagaki K, Tsukagoshi S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers and their related complexes. *Gann* 1976;67:921–922.
- Burchenal J, Irani G, Kern K, et al. 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. *Rec Res Cancer Res* 1980;74:146–155.
- Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. *Biochem Pharmacol* 1996;52:1855–1865.
- Shimada M, Itamochi H, Kigawa J. Nedaplatin: a cisplatin derivative in cancer therapy. *Cancer Manag Res* 2013;5:67–76.
- Fojo T, Farrell N, Ortuzar W, et al. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. *Crit Rev Oncol Hematol* 2005;53:25–34.
- Bates SE, Amiri-Kordestani L, Giaccone G. Drug development: portals of discovery. *Clin Cancer Res* 2012;18:23–32.
- Kelland L. The development of orally active platinum drugs. In: Lippert B, ed. *Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug*. Zurich: Verlag Helvetica Chimica Acta; 1999:497.
- Farrell N, Qu Y, Bierbach U, et al. Structure-activity relationships within di- and trinuclear platinum phase-I clinical anticancer agents. In: Lippert B, ed. *Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug*. Zurich: Verlag Helvetica Chimica Acta; 1999:477–496.
- Holford J, Sharp S, Murrer B, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. *Br J Cancer* 1998;77:366–373.
- Flaherty KT, Stevenson JP, Redlinger M, et al. A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine. *Cancer Chemother Pharmacol* 2004;53:404–408.
- Park GY, Wilson JJ, Song Y, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. *Proc Natl Acad Sci U S A* 2012;109:11987–11992.
- Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. *Pharmacol Ther* 1987;34:155–166.
- Zhu G, Song L, Lippard SJ. Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells. *Cancer Res* 2013;73:4451–4460.
- Martens-de Kemp SR, Dalm SU, Wijnolts FM, et al. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. *PLoS One* 2013;8:e61555.
- Blommaert F, van Kijk-Kuijnenburg H, Dijt F, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. *Biochemistry* 1995;34:8474–8480.
- Scheef E, Briggs J, Howell S. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. *Mol Pharmacol* 1999;56:633–643.
- Enoui M, Jiricny J, Schärer OD. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. *Nucleic Acids Res* 2012;40:8953–8964.
- Zhu G, Song L, Lippard SJ. Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells. *Cancer Res* 2013;73:4451–4460.
- Sorenson C, Eastman A. Mechanism of cis-diamminedichloroplatin(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. *Cancer Res* 1988;48:4484–4488.
- Toney J, Donahue B, Kellett P, et al. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatin. *Proc Natl Acad Sci U S A* 1989;86:8328–8332.
- Bruhn S, Pil P, Essigmann J, et al. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. *Proc Natl Acad Sci U S A* 1989;89:2307–2311.
- Hughes EN, Engelsberg BN, Billings PC. Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2. *J Biol Chem* 1992;267:13520–13527.
- Ramachandran S, Temple BR, Chaney SG, et al. Structural basis for the sequence-dependent effects of platinum-DNA adducts. *Nucleic Acids Res* 2009;37:2434–2448.
- Ramachandran S, Temple B, Alexandrova AN, et al. Recognition of platinum-DNA adducts by HMGBl. *Biochemistry* 2012;51:7608–7617.
- Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. *Cancer Res* 1997;57:1841–1845.
- Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer* 2007;7:573–584.
- Vasilevska IA, Rikitina TV, O'Dwyer PJ. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. *Mol Pharmacol* 2004;65:235–243.
- Vasilevska IA, Selvakumar M, O'Dwyer PJ. Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin. *Mol Pharmacol* 2008;74:246–254.
- Maestre N, Tritton TR, Laurent G, et al. Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. *Cancer Res* 2001;61:2558–2561.
- Roodhart JM, Daenen LG, Stigter EC, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. *Cancer Cell* 2011;20:370–383.
- Beatty GL, Chiorean EG, Fishman MP, et al. CD40 regulates cancer inflammation and induces regression of pancreatic carcinoma in mice and humans. *Science* 2011;331:1612–1616.
- Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. *Oncogene* 2012;31:1869–1883.
- Lin X, Okuda T, Holzer A, et al. The copper transporter CTR1 regulates cisplatin uptake in *Saccharomyces cerevisiae*. *Mol Pharmacol* 2002;62:1154–1159.
- Blair BG, Larson CA, Safaei R, et al. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. *Clin Cancer Res* 2009;15:4312–4321.
- Samimi G, Varki NM, Wilczynski S, et al. Increase in the expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. *Clin Cancer Res* 2003;9:5853–5859.
- Britten RA, Green JA, Broughton C, et al. The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells. *Biochem Pharmacol* 1991;41:647–649.
- Mistry P, Kelland L, Abel G, et al. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. *Br J Cancer* 1991;64:215–220.
- Godwin A, Meister A, O'Dwyer P, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase in glutathione synthesis. *Proc Natl Acad Sci U S A* 1992;89:3070–3074.
- Hamilton T, Winker M, Louie K, et al. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion. *Biochem Pharmacol* 1985;34:2583–2586.
- Koberle B, Grimaldi K, Sunters A, et al. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. *Int J Cancer* 1997;70:551–555.
- Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. *Clin Cancer Res* 2008;14:1291–1295.
- Selvakumar M, Piscarcik DA, Bao R, et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. *Cancer Res* 2003;63:1311–1316.
- Hubner RA, Riley RD, Billingham LJ, et al. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. *PLoS One* 2011;6:e25164.
- De Dosso S, Zanellato E, Nucifora M, et al. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. *Cancer Chemother Pharmacol* 2013;72:159–165.
- Squires MH 3rd, Fisher SB, Fisher KE, et al. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. *Cancer* 2013;119:3242–3250.

58. Yamada Y, Boku N, Nishina T, et al. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. *Ann Oncol* 2013;24:2560–2565.
59. Friboulet L, Olausson KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. *N Engl J Med* 2013;368:1101–1110.
60. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005;434:913–917.
61. Farmer H, McCabell N, Lord C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–921.
62. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. *Nature* 2008;451:1111–1116.
63. Sakai W, Swisher EM, Karlan BM, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 2008;451:1116–1121.
64. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. *Lancet Oncology* 2011;12:852–861.
65. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 2008;132:27–42.
66. Matthew R, Karantz-Wadsworth V, White E. Role of autophagy in cancer. *Nat Rev Cancer* 2007;7:961–967.
67. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. *J Clin Invest* 2007;117:326–336.
68. Duffull S, Robinson B. Clinical pharmacokinetics and dose optimization of carboplatin. *Clin Pharmacokinet* 1997;33:161–183.
69. Harland S, Newell D, Siddik Z, et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. *Cancer Res* 1984;44:1693–1697.
70. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. *Clin Cancer Res* 2000;6:1205–1218.
71. Gamelin E, Bouil A, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. *Clin Cancer Res* 1997;3:891–899.
72. Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. *Semin Oncol* 1998;25:13–22.
73. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. *J Natl Cancer Inst* 1995;87:573–580.
74. Jodrell D, Egorin M, Canetta R, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. *J Clin Oncol* 1992;10:520–528.
75. Reyno L, Egorin M, Canetta R, et al. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. *J Clin Oncol* 1993;11:1156–1164.
76. Shen DW, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. *Pharmacol Rev* 2012;64:706–721.
77. Ma J, Verweij J, Planting A, et al. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. *Br J Cancer* 1995;71:512–517.
78. Schellens J, Ma J, Planting A, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. *Br J Cancer* 1996;73:1569–1575.
79. Ozols R, Corden B, Jacob J, et al. High-dose cisplatin in hypertonic saline. *Ann Intern Med* 1984;100:19–24.
80. Howell S, Pfeifle C, Wung W, et al. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. *Cancer Res* 1983;43:1426–1431.
81. Alberts D, Liu P, Hannigan E, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med* 1996;335:1950–1955.
82. Solomon B, Soulen M, Baum R, et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. *J Vasc Interv Radiol* 1999;10:793–798.
83. Extra J, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin. *Semin Oncol* 1998;25:13–22.
84. Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (L-OHP): global safety in 682 patients. *Proc Am Soc Clin Oncol* 1995;14:209.
85. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004;350:2343–2351.